Century Therapeutics, INC Form 4 insider transactions

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock at an average price of $3.0979 under a pre-arranged trading plan.

Brent Pfeiffenberger, CEO of Century Therapeutics, received stock options and restricted stock units (RSUs) on March 7, 2024, according to a Form 4 filing with the SEC.

Douglas Carr, SVP of Finance & Operations at Century Therapeutics, reports the acquisition of 14,000 shares of common stock and options to purchase 81,000 shares.

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, received stock options and restricted stock units (RSUs) according to a recent SEC Form 4 filing.

Adrienne Farid, Chief Operations Officer of Century Therapeutics, reports the acquisition of stock and option grants.

Hyam Levitsky, President of R&D at Century Therapeutics, reports the acquisition of restricted stock units and stock options.

Adrienne Farid, Chief Operations Officer of Century Therapeutics, exercised stock options and sold shares of common stock on March 6th and 7th, 2024, under a pre-arranged trading plan.